Neurologia medico-chirurgica
Online ISSN : 1349-8029
Print ISSN : 0470-8105
ISSN-L : 0470-8105
62 巻, 7 号
選択された号の論文の7件中1~7を表示しています
Special Topic
Original articles
  • Eiichirou URASAKI, Yasushi MIYAGI, Shogo MURAMATSU, Yasutaka EZAKI
    2022 年 62 巻 7 号 p. 313-321
    発行日: 2022/07/15
    公開日: 2022/07/15
    [早期公開] 公開日: 2022/05/10
    ジャーナル オープンアクセス

    Spinal cord stimulations have been used widely to treat intractable neuropathic pain. The conventional spinal cord stimulation paradigm, the "tonic" type, suppresses excessive activation of wide dynamic range neurons in the dorsal horn via the collateral branch from the dorsal column. Therefore, preserved dorsal column function is an important prerequisite for tonic spinal cord stimulations. A tonic spinal cord stimulation requires eliciting paresthesia in the painful area due to stimulation of the dorsal column and dorsal root. Recent spinal cord stimulation paradigms, including burst and high-dose, are set below the paresthesia threshold and are proposed to have different pain reduction mechanisms. We conducted an interference study of these different stimulation paradigms on the somatosensory evoked potential (SEP) to investigate differences in the sites of action between tonic and new spinal cord stimulations. We recorded posterior tibial nerve-stimulated SEP in seven patients with neuropathic pain during tonic, burst, and high-dose stimulations. The total electrical energy delivered was calculated during SEP-spinal cord stimulation interference studies. High-dose stimulations could not reduce the SEP amplitude despite higher energy delivery than tonic stimulation. Burst stimulation with an energy similar to the tonic stimulation could not reduce SEP amplitude as tonic stimulation. The study results suggested different sites of action and effects on the spinal cord between the conventional tonic and burst or high-dose spinal cord stimulations.

  • Takahiro SASAKI, Yuji UEMATSU, Junya FUKAI, Shota TANAKA, Akitake MUKA ...
    2022 年 62 巻 7 号 p. 322-327
    発行日: 2022/07/15
    公開日: 2022/07/15
    [早期公開] 公開日: 2022/05/10
    ジャーナル オープンアクセス
    電子付録

    To assess the clinicopathological features and prognostic factors of pediatric intracranial ependymomas and to explore the current diagnostic practice, we analyzed clinical data from the Brain Tumor Registry of Japan (BTRJ). Data of fifty children under 18 years of age diagnosed with intracranial ependymoma were extracted from the BTRJ database. Cases were reviewed for overall survival (OS) and progression-free survival (PFS), with attention to gender, preoperative Karnofsky performance status score, location of the tumor, the extent of resection, World Health Organization (WHO) histopathological grading, and adjuvant therapy. The median age at diagnosis was 6.1 years, ranging from 7 months to 17.6 years. Based on the WHO histopathological grading, 27 patients were classified under grade 2 (54%) and 23 patients were classified under grade 3 (46%). Gross total resection (GTR) was achieved in 30 patients (60%). The median follow-up time was 65 months. Five-year PFS and OS were 47.2 ± 7.3% and 73.3 ± 6.7%, respectively. GTR was associated with longer OS (P = 0.02). The histopathological grading was not an independent prognostic factor for the OS. Mitosis and microvascular proliferation were higher among patients with grade 3 than in those with grade 2, which aided in deciding the WHO grade. This nationwide study revealed the characteristics and outcomes of patients with childhood ependymomas. GTR was the factor most consistently associated with improved survival. In contrast, the histopathological grading in this cohort was not a significant prognostic factor. More reproducible and practical criteria for the diagnosis of intracranial ependymomas should be further pursued in future studies.

  • Yu FUJII, Toshihiro OGIWARA, Hiroto KATO, Yoshiki HANAOKA, Ridzky Firm ...
    2022 年 62 巻 7 号 p. 328-335
    発行日: 2022/07/15
    公開日: 2022/07/15
    [早期公開] 公開日: 2022/05/25
    ジャーナル オープンアクセス

    Factors predicting adverse events following implantation with wafers containing 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine, BCNU), which is used in local chemotherapy for malignant gliomas (MGs), are unknown. The association between cerebral edema (CE), which often occurs after implantation, and perioperative seizures, which are often observed in MG cases, is under debate. This study investigated risk factors for CE associated with BCNU wafer implantation and their relationship with perioperative seizures. A total of 31 surgical cases involving 28 adult patients who underwent BCNU wafer implantation for MGs were investigated and classified into those with and without postoperative transient CE. We assessed the correlations between CE caused by BCNU implantation and various factors, including postoperative epileptic seizures. World Health Organization (WHO) grade III MGs significantly affected postoperative CE (p = 0.003) and the occurrence of seizures (p = 0.0004). Factors predictive of postoperative seizures were WHO grade III MGs (p = 0.0026), increased postoperative CE (p = 0.0272), and history of preoperative seizures (p = 0.0316). Postoperative CE, WHO grade III MGs, and a history of preoperative seizures might predict the postoperative occurrence of seizures, necessitating stringent management of seizures and CE in the affected patients.

Technical Notes
  • Rio HIGAKI, Shinya YAMAGUCHI, Hironori HARUYAMA, Masato OSAKI, Shuji A ...
    2022 年 62 巻 7 号 p. 336-341
    発行日: 2022/07/15
    公開日: 2022/07/15
    [早期公開] 公開日: 2022/05/25
    ジャーナル オープンアクセス

    Cerebral venous thrombosis (CVT) is a rare cause of stroke, and the first-line treatment is systemic anticoagulation. Patients unresponsive to standard therapy for CVT present with rapid neurological deterioration and require endovascular treatment. We encountered two patients with severe CVT who underwent endovascular treatment. In our cases, the thrombus was too hard and extensive to pass through using currently existing techniques. We performed the "digging through thrombus technique" using an aspiration catheter and stent retriever and achieved rapid sinus recanalization and favorable outcomes.

  • Manabu SASAKI, Takanori FUKUNAGA, Koshi NINOMIYA, Masao UMEGAKI, Katsu ...
    2022 年 62 巻 7 号 p. 342-346
    発行日: 2022/07/15
    公開日: 2022/07/15
    [早期公開] 公開日: 2022/05/25
    ジャーナル オープンアクセス

    This study aims to present our surgical technique of lateral lumbar interbody fusion (LLIF) without corpectomy for lumbar vertebral fracture (LVF) associated radiculopathy. This study includes three patients treated with LLIF (mean age of 77.3 years, Group L) and three patients treated with PLIF (mean age of 75.7 years, Group P) to compare the surgical outcomes. The cartilage on the fractured vertebrae was aggressively resected with attention to avoid injury to the ring apophysis. The central cavity of the fractured endplate was filled with a bone graft substitute made of hydroxyapatite and collagen composite, followed by interbody fusion achieved by utilizing of a cage with sufficient length spanning the bilateral edges of the fractured vertebra. PLIF was performed with a standard technique using two interbody cages, and vertebroplasty was combined in one patient. Comparing to PLIF, LLIF could be performed with less estimated blood loss in shorter surgical time. Local kyphotic angle improved in all cases of Group L immediately after the surgery, but correction loss was observed at the final examination. The lordotic angle was lost in Group P postoperatively. Arthrodesis was achieved in all the cases. The mean VAS score for leg pain was 85.3 mm in Group L and 82.0 mm in Group P at preoperation and decreased to 8.7 mm and 11.3 mm, respectively, at postoperation. LLIF is an effective surgical option that enables stabilization of the fractured vertebra and reduces radicular pain by indirect neural decompression.

Editorial Committee
feedback
Top